Kairos Pharma Ltd. Reports Positive Safety Results in Phase 2 Study of Prostate Cancer Drug ENV-105

Kairos Pharma Ltd. (NYSE American: KAPA) has reported positive interim safety results from its ongoing Phase 2 trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer. The study, involving the first ten patients, revealed no dose-limiting toxicities or unexpected adverse events, with ENV-105 being well tolerated in combination with apalutamide, a standard hormone therapy. The trial, which includes 100 patients across prestigious institutions such as Cedars-Sinai, City of Hope, and Huntsman Cancer Center, is set to provide interim efficacy data by September 2025. These findings are crucial as they pave the way for potential Phase 3 studies and highlight the drug's safety profile in treating a challenging form of cancer.